Biocon Limited — Important, 10-04-2025: Updates

The quarterly certificate confirms that Biocon Limited's Commercial Paper (CP) issuance adhered to its stated purposes, with proceeds fully utilized for the acquisition of equity in a subsidiary. Total CP issuance reached ₹570 Crore during the calendar year up to March 2025. The company has maintained compliance with listing conditions, and there have been no material changes affecting its financial status or credit rating. This indicates a stable financial position, suggesting a positive outlook for ongoing operations and financing activities. Investors should watch closely for future developments related to the subsidiary acquisition and overall growth strategy.